Tag: Cellular Engineering

Cellular engineering applies the principles and methods of engineering to the problems of cell and molecular biology of both a basic and applied nature. As biomedical engineering has shifted from the organ and tissue level to the cellular and sub-cellular level, cellular engineering has emerged as a new area. A cornerstone of much of this activity is cell culture technology, i.e., the ability to grow living cells in the artificial environment of a laboratory. Cellular engineering includes the role of engineering in both basic cell biology research and in the making of products which use living cells, e.g., tissue engineering and bioprocess engineering. The former involves the use of living cells in the development of biological substitutes for the restoration or replacement of function, and the latter the use of living cells to manufacture a biochemical product, e.g., through the use of recombinant DNA technology. In fact, as biomedical engineering has expanded to include the cellular level, and bioprocess engineering has shifted in interest from microbial organisms to include mammalian cells, there are intellectual issues in which an interest is shared by these two formerly separate areas of engineering activity. Cellular engineering thus transcends the field of biomedical engineering.

Novo Nordisk got the Beacon® Optofluidic platform

Berkeley Lights, Inc. and Novo Nordisk today announced that Novo Nordisk has purchased the Beacon® Optofluidic platform to accelerate workflows in cell line development and to use the platform for fut...

Scientists developed the first fully personalized tissue implant

The new technology makes it possible to engineer any kind of tissue implant from one small fatty tissue biopsy.

Eurofins has become a distributor of Synthego genome engineering products

Eurofins Genomics, a global leader in bioanalytical testing, announced it will distribute Synthego's synthetic single guide RNA (sgRNA) to their global customer database across 44 countries.

Lonza and Sartorius Stedim Biotech update their partnership

Lonza (Switzerland) and Sartorius Stedim Biotech (Germany) announced that they have modified their current agreement for supply of cell culture media by mutual accord.

CRISPR Therapeutics and MaxCyte expanded their drug development partnership

CRISPR Therapeutics and MaxCyte announced the expansion of their existing relationship by entering into an agreement that will allow to develop CRISPR/Cas9-based therapies in immuno-oncology.

Abzena expands its biotherapeutics offering with $20 million investment

Abzena, a life sciences group with its headquarters in the UK, announced $20 million investment into expansion of its integrated biotherapeutics offering (Biologics Drug Substance and ADC).

Emerging UK collaboration will help to promote biomedical research

The purpose of the collaboration is to identify and establish projects focused on the development of human 3D cell models and robust cellular platforms.

Korean scientists unveiled biosensor for optimizing microbial cell factories

A research group at Korea Advanced Institute of Science and Technology (KAIST) presented a novel biosensor which can produce diverse, high-level microbial cell factories.

Russia approved the provision of licensing activities for production of BMCP

The Prime Minister of Russia, Dmitry Medvedev, signed a decree approving a regulation on licensing activities for the production of biomedical cell products (BMCP).

Abzena and Tmunity will develop new CAR-T therapies

Abzena has signed an antibody humanisation agreement with Tmunity Therapeutics, a clinical stage T cell therapy company and a leader in the development of new CAR-T therapies.

Sulk Institute scientists reported a novel gene-editing tool

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions , announced a commercial supply agreement with Aucta Pharmaceuticals.

Pall Corporation sets up a strategic partnership with Celltheon

Pall Corporation has formed a strategic partnership with Celltheon Corporation, an experienced cell line and expression technology platform development company.

Oxford Genetics signs major contract for CRISPR engineered mammalian cell lines

Oxford Genetics has secured a multi-million pound contract with a leading multi-billion dollar global ecommerce provider of reagents and tools to the research and clinical community.

Torque revealed its high-efficiency T cell manufacturing platform

Torque, an immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics announced a high-efficiency T cell manufacturing process called "Slipstream".

Newcells Biotech received funding for development of hiPSC technology

The funding will allow the company to expand its current capabilities, accelerating plans to develop and launch new cell-based assays for pre-clinical drug discovery and development.

Natera succeeded in PCR technology

Natera, a leader in cell-free DNA analysis, announces a powerful new kidney transplant rejection biomarker and study results in collaboration with the University of California, San Francisco, a recognized leader in transplanta